The carrier designis fully customizable and can facilitate theidentification of potential biomarkers and proteins implicated inneurodegenerative disorders and diseases caused by protein misfoldingand aggregation, including cancers associated with p53 aggregation.58 This technology can be adapted to target differentprotein biomarkers in various diseases by simply replacing the aptamersequences. The gene discussed is TP53; the disease is cancer.